Posts tagged "harm-reduction"

Testosterone Cypionate

The most prescribed testosterone ester in the US, with an 8-day half-life that makes it the backbone of modern TRT. What the clinical data actually says about how to use it.

Evidence-graded profile of testosterone cypionate: pharmacokinetics, subcutaneous vs intramuscular data, the TRAVERSE trial's cardiovascular findings, age-stratified risk, and where peptides fit alongside.

testosterone-cypionatetrtdepo-testosteroneharm-reductioncypionate

TestosteroneTRT+

Testosterone Enanthate

The most prescribed testosterone ester outside the US, with a 4.5-7 day half-life that demands weekly dosing for stable levels. What the clinical data says about the hepcidin hijack, erythrocytosis, and why dosing frequency matters more than dose size.

Evidence-graded profile of testosterone enanthate: the hepcidin mechanism behind erythrocytosis, DHT and the scrotal paradox, dosing frequency pharmacokinetics, the TRAVERSE prostate saturation model, age-stratified risk, and peptide alternatives.

testosterone-enanthate

TestosteroneTRT+

Testosterone Propionate

The first synthetic testosterone ester (1936), with a 2-4.5 day half-life that demands daily or EOD dosing. What the clinical data says about the fertility paradox, rapid washout safety, microdosing, and why this 'relic' is the precision tool of modern endocrinology.

Evidence-graded profile of testosterone propionate: the fastest-acting injectable ester, its fertility paradox from murine data, the washout safety net for women and diagnostics, PIP solutions through microdosing, circadian alignment, age-stratified risk, and peptide alternatives.

testosterone-propionate

harm-reduction

harm-reduction

Protocols

Testosterone Cypionate

Testosterone Enanthate

Testosterone Propionate

Protocols

Testosterone Cypionate

Testosterone Enanthate

Testosterone Propionate